Skip to content
OpenCapital
Get started

NAGE NAGE Pharmaceuticals segment — Gain On Settlement Of Royalty Obligation

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXPharmaceuticals — income (loss)
$1.03B+59.6%
Baxter International logo
BAXPharmaceuticals — Segment operating income
$46M-27.0%
Roivant Sciences logo
ROIVReportable Segment — Gain on litigation settlement
$192.56M—
Amneal Pharmaceuticals, Inc. logo
AMRXAffordable Medicines — Gain (Loss) from Litigation Settlement
-$694K—
Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Revenue
$214.27M+55.5%
Rigel Pharmaceuticals logo
RIGLDelivery of drug supplies, royalties and others — Revenue recognized
$3.9M-42.6%

Other financials

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Cash & equivalents$66.5M+19.7%
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation

See full
Market cap$254.07M-74.9%
Enterprise value$190.09M-79.7%
P/E13.6×-43.5×
P/S2×-6.8×

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp
FCF margin-70.4%—

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0×0.0×
Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept cdxc:GainOnSettlementOfRoyaltyObligation.

The official record: NAGE’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's pharmaceuticals segment — gain on settlement of royalty obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NAGE's pharmaceuticals segment — gain on settlement of royalty obligation?
NAGE (NAGE) reported pharmaceuticals segment — gain on settlement of royalty obligation of $0 in Q4 2025.
What does pharmaceuticals segment — gain on settlement of royalty obligation mean?
This metric captures the non-recurring financial gain recognized when the company successfully negotiates or settles a contractual obligation related to royalty payments for its pharmaceutical assets. Such gains often reflect a strategic restructuring of intellectual property costs or the resolution of long-term licensing liabilities. Investors analyze this to distinguish between core operational performance and one-time accounting adjustments that impact segment profitability.